UnitedHealth Group Inc UNH reported Q1 FY22 sales of $80.1 billion, up 14.2% Y/Y, beating the consensus of $78.76 billion, with double-digit growth at both Optum and UnitedHealthcare.
- Adjusted EPS of $5.49 surpassed the consensus of $5.37 and was better than $5.31 a year ago.
- The company generated an operating cash flow of $5.3 billion or 1.0x net income.
- The medical care ratio was 82% compared to 80.9% a year ago due to COVID effects and business mix.
- The operating cost ratio of 14.2% decreased from 14.6% in Q1 FY21 due to COVID effects and continued productivity advances, partially offset by business mix and investments.
- Related: UnitedHealth Scoops Up Home-Health Firm LHC Group In $5.4B Deal.
- UnitedHealthcare segment Q4 revenues grew 13.6% to $62.6 billion compared to last year, with operating earnings of $3.8 billion compared to $4.1 billion last year.
- Optum segment sales were up 18.9% to $43.3 billion, and operating earnings rose to $3.2 billion from $2.6 billion a year ago.
- Guidance: UnitedHealth expects FY22 adjusted EPS of $21.20 - $21.70, up from prior outlook of $21.10 - $21.60.
- Price Action: UNH shares closed 0.21% lower at $536.80 during after-hours trading on Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in